HERA: Key Design Elements, Results and Future Plans
   
  1. Hera: Key Design Elements, Results and Future Plans
  2. First Results of the Hera Trial
  3. Accrual: 5090 Women 478 centers from 39 countries (2002-2005)
  4. Hera Trial Design
  5. Key Differences
  6. Key Inclusion Criteria
  7. Endpoints and Analysis Plan
  8. Hera Flow Chart
  9. Patient/Tumor Characteristics
  10. Patient/Tumor Characteristics
  11. Patient/Tumor Characteristics
  12. Adjuvant Endocrine Therapy
  13. Overview of Adverse Events
  14. Safety Analysis Polulation Cardiotoxicity
  15. Disease-Free Survival
  16. Disease-Free Survival Type of First Event
  17. DFS Benefit in Subgroups HR: 1 year trastuzumab vs observation
  18. Secondary Efficacy Endpoints Intent-to-treat Analysis
  19. Conclusions: 1
  20. Conclusions: 2
  21. Conclusions: Overall
  22. Follow-up: 1
  23. ER-Negative and ER Positive; Study 8541
  24. ER-Negative and ER Positive; Study9741
  25. Hera Trial Design
  26. Follow-up: 2

Brian Leyland-Jones, MD, PhD